Clontech Laboratories announces launch of DNA SMART ChIP-Seq Kit

NewsGuard 100/100 Score

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of the DNA SMART ChIP-Seq Kit. This kit adapts Clontech's patented SMART® technology in an innovative manner for use with low-input samples, including both dsDNA and ssDNA templates, to generate ChIP-seq libraries for NGS.

SMART (Switching Mechanism at 5' End of RNA Template) technology, when applied to RNA, allows for full-length cDNA synthesis with direct addition of a PCR adaptor. In the DNA SMART ChIP-Seq Kit, a novel, patent-pending adaptation of template switching technology is used to add Illumina®-specific adaptors directly to DNA. This produces ChIP-seq libraries without additional ligation or clean-up steps. The process has resulted in the simplification of library generation, cutting down protocol time significantly compared to traditional, ligation-based methods of adapter addition. The DNA SMART ChIP-Seq Kit generates libraries with good complexity and low redundancy from low-input samples (100 pg–10 ng) using a simple protocol that can be completed in half a day.

"Clontech is known as a leader in cDNA synthesis, and in recent years SMART technology has been widely acclaimed as the gold standard for sensitive transcriptome analysis from low-input samples, including single cells," said Carol Lou, General Manager of Clontech Laboratories, Inc. "With the DNA SMART ChIP-Seq Kit we are able to expand the benefits of SMART technology into other NGS applications. Our focus has been providing new solutions to customers, enabling them to work with challenging samples. This kit allows us to address the needs of those researchers working with low inputs of either dsDNA or ssDNA for NGS applications."

The launch of the DNA SMART ChIP-Seq Kit continues the Clontech® tradition of supporting good science by providing new tools to meet the ever-changing needs of life science researchers.

SOURCE Clontech Laboratories, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tracking circulating tumor DNA could indicate gastroesophageal cancer treatment response